Special Issue "Primary and Continued Cell Cultures"
Deadline for manuscript submissions: 8 July 2025 | Viewed by 7143
2. Departments of Pathology and Urology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Interests: cell reprogramming; telomerase and telomeres; patient-derived models; cell therapies; living biobanks; viruses; cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue in Viruses: Conditional Cell Reprogramming: Applications in Virology
Special Issue in Cells: Reprogrammed Cells in Disease Modeling and Drug Discovery II
Special Issue in Organoids: Organoids and Cancer Models
Traditional cancer cell lines and transformed cell lines are widely used in medical research. These cells usually have abnormalities resulting from the original tumor itself, but may also develop abnormalities due to genetic manipulation, or due to genetic and epigenetic changes during long-term passage. Primary cultures may maintain the lineage functions of their original tissue types, yet their life span and population doubling time are limited due to the nature of cellular senescence. Primary cultures usually have low yields and high variability compared to original tissue specimens, limiting their applications in research. Conditional cell reprogramming (CR) makes it possible to rapidly expand and continually culture primary cells from surgical specimens, core or needle biopsies, and other minimally invasive or noninvasive specimens—for example, nasal cavity brushing from a variety of species, including human, mouse, rat, horse, and ferret. These conditionally reprogrammed cells (CRCs) preserve their lineage functions and provide biologically relevant and physiological conditions suitable for studies of toxicity, virology, and tissue repair and the discovery of antiviral or anticancer drugs. This Special Issue will focus on primary cell cultures (protocols, reviews, and original articles) using conditionally reprogrammed cells, organoids, and other recent approaches.
Prof. Dr. Xuefeng Liu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- primary normal cells
- primary tumor cells
- patient-derived cells
- CRC (conditionally reprogrammed cells)
- circulating tumor cells
- human diseases
- cancer models
- drug discovery